This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dupuis, A.
Right arrow Articles by Venisse, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dupuis, A.
Right arrow Articles by Venisse, N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2009, p. 798-799, Vol. 53, No. 2
0066-4804/09/$08.00+0     doi:10.1128/AAC.01126-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Preparation and Stability of Voriconazole Eye Drop Solution{triangledown}

Antoine Dupuis,1,2* Nicolas Tournier,1 Gwenaël Le Moal,1 and Nicolas Venisse1

Centre Hospitalier Universitaire de Poitiers, Poitiers, France,1 Faculté de Médecine et de Pharmacie, Université de Poitiers, Poitiers, France2

Received 22 August 2008/ Returned for modification 10 September 2008/ Accepted 29 October 2008

The combined systemic and topical administration of voriconazole has successfully been used to treat keratomycosis. Because no voriconazole eye drop product is commercially available, we prepared a sterile eye drop solution (10 mg/ml). Voriconazole remains stable over 30 days, providing an eye drop solution suitable for use for the topical treatment of fungal keratitis.

* Corresponding author. Mailing address: CHU Poitiers, Service Pharmacie, BP 577, 86021 Poitiers cedex, France. Phone: 33549443801. Fax: 33549443972. E-mail: Antoine.Dupuis{at}univ-poitiers.fr

{triangledown} Published ahead of print on 10 November 2008.

Antimicrobial Agents and Chemotherapy, February 2009, p. 798-799, Vol. 53, No. 2
0066-4804/09/$08.00+0     doi:10.1128/AAC.01126-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Al-Badriyeh, D., Leung, L., Davies, G. E, Stewart, K., Kong, D. (2009). Successful Use of Topical Voriconazole 1% Alone as First-Line Antifungal Therapy Against Candida albicans Keratitis. The Annals of Pharmacotherapy 43: 2103-2107 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»